Malignant Hyperthermia (MH)
Gene or Region: RYR1
Reference Variant: C
Mutant Variant: G
Affected Breeds: Quarter Horse
Research Confidence: High confidence, findings reproduced multiple studies
Explanation of Results: MH/MH = homozygous for Malignant Hyperthermia, trait expressed MH/n = heterozygous for Malignant Hyperthermia, trait expressed n/n = no variant detected
General Description for Malignant Hyperthermia
Malignant Hyperthermia (MH) is a muscle disorder in which anesthesia, stress, or extreme exercise trigger a hyperthermic state. Symptoms include high temperature, increased heart rate, high blood pressure, sweating, acidosis, and muscle rigidity. If symptoms are not immediately resolved, death is likely to occur. As this condition is autosomal dominant, even horses with a single allele (MH/n) exhibit symptoms. One study has shown that horses with both MH and polysaccharide storage myopathy (PSSM) have more severe clinical symptoms.
Gene Information
RYR1 is involved in the control of calcium channels within the muscle. Mutations in both humans and swine have been shown to cause conditions similar to MH seen in the horse. This mutation is a single base substitution that alters an amino acid, likely affected the function of the encoded protein.
References
Aleman M et al., “Association of a mutation in the ryanodine receptor 1 gene with equine malignant hyperthermia.” (2004) Muscle Nerve. 30: 356-65. PMID: 15318347
McCue ME et al., “Polysaccharide storage myopathy phenotype in quarter horse-related breeds is modified by the presence of an RYR1 mutation.” (2009) Neuromuscul Disord. 19: 37-43. PMID: 19056269
Aleman M et al., “Malignant hyperthermia associated with ryanodine receptor 1 (C7360G) mutation in Quarter Horses.” (2009) J Vet Intern Med. 23: 329-34. PMID: 19220734
More Horse Health
Equine Metabolic Syndrome / Laminitis Risk
Equine Metabolic Syndrome (EMS) is a wide-spread issue in the horse population. Primarily characterized by hyperinsulinemia (excess insulin circulating in the blood in relation to glucose levels), this metabolic disorder is often present in obese horses and ponies and can be challenging to diagnose as it can be misdiagnosed as "Cushing's" (a pituitary disfunction).
Equine Recurrent Uveitis Risk and Severity
Equine Recurrent Uveitis (ERU) is the most common cause of blindness in horses, affecting about 3-15% of the horse population worldwide. Characterized by episodes of inflammation of the middle layer of the eye, Equine Recurrent Uveitis in horses leads to the development of cataracts, glaucoma and eventually complete loss of vision.
Foal Immunodeficiency Syndrome
Foal immunodeficiency syndrome (FIS) is a failure in the development of the adaptive immune system. At 3-6 weeks of age, once the maternal antibodies begin to degrade, foals exhibit signs of anemia, diarrhea, and pneumonia. As these foals fail to respond to treatment for infections, they are humanely euthanized at a young age.
Glanzmann Thrombasthenia
Glanzmann Thrombasthenia (GT) is a blood platelet function disorder, resulting from a reduction in the platelet fibrinogen receptor protein. Clinical signs can be characterized by bleeding on the skin or from the mouth/nostril/gastrointestinal mucosas, and may include skin rashes with blood spots under the skin, nasal bleeding, gastrointestinal and gingival bleedings.